NASH crash hits another Bay Area ‘fatty liver’ drug hopeful

Several Bay Area companies are developing drugs against nonalcoholic steatohepatitis, a disease linked to obesity and diabetes, with a potential market of $40 billion in drug sales a year.

Click to view original post